Palatin Technologies announced the sale of Vyleesi to Cosette Pharmaceuticals for up to $171M, consisting of an upfront purchase price of $12M plus contingent, sales-based milestone payments of up to $159M. Vyleesi is the first and only as-needed treatment approved by the FDA for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PTN:
- Palatin: NYSE American accepts listing standards compliance plan
- Palatin files to sell 2.48M shares of common stock for holders
- Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
- Palatin reports Q1 EPS (48c) vs. (86c) last year
- Biotech Alert: Searches spiking for these stocks today
